XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended Jun...(399 399 399 Other curre...)

Other current liabilities 565 -- --

--------- --------- ---------

Total current liabilities 4,094 3,104 3,402

--------- --------- ---------

LIABILITY IN RESPECT OF EMPLOYEE

SEVERANCE OBLIGATIONS 188 444 340

DEFERRED GAIN 198 598 398

COMMITMENTS AND CONTINGENCIES

--------- --------- ---------

Total liabilities 4,480 4,146 4,140

--------- --------- ---------

SHAREHOLDERS' EQUITY:

Ordinary shares of NIS 0.02 par value

(authorized 300,000,000 as of June

30, 2007, June 30, 2006 and

December 31, 2006, issued and

Outstanding 220,154,349,

220,069,801 and 220,124,349 as of

June 30, 2007, June 30, 2006 and

December 31, 2006, respectively) 1,072 1,072 1,072

Additional paid in capital 137,583 135,667 136,611

Deficit accumulated during the

development stage (129,572) (107,082) (114,923)

--------- --------- ---------

Total shareholders' equity 9,083 29,657 22,760

--------- --------- ---------

Total liabilities and shareholders'

equity 13,563 33,803 26,900

========= ========= =========

Interim Consolidated Statements of Operations for the Six

Months Ended June 30, 2007 and 2006 (unaudited)

(in thousa
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd Copyright©2007 PR Newswire.

0 GOOD